KPTI News and Press, Karyopharm Therapeutics Inc. From 07/25/19

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI ) investors concerning the Company and its officers’ possible violations of federal sec...

New York, New York--(Newsfile Corp. - July 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff in a f...

Chiasma (NASDAQ: CHMA ) +21%  as Mycapssa successful in late-stage acromegaly study. More news on: Chiasma, Inc., Realogy Holdings Corp., Diffusion Pharmaceuticals Inc., Stocks on the move, Read more ...

Karyopharm Therapeutics ( KPTI ) was able to obtain FDA accelerated approval for its drug selinexor (to be marketed as Xpovio) for penta-refractory Multiple Myeloma ((MM)). This approval is good news for the biotech as it sets out to eventually obtain other regulatory approvals in MM and in ...

"A ship is safe in harbor, but that's not what ships are for ." - John A. Shedd One of the big winners in the market last week and for the model portfolio of The Busted IPO Forum was a small-cap oncology concern named Karyopharm Therapeutics ( KPTI ). The stock soared just over 45% th...

Karyopharm Therapeutics (NASDAQ: KPTI ) is up 3% on its return to regular-session trading after it spiked 36% in Wednesday's shortened session amid an FDA approval for its selinexor , for treatment of penta-refractory multiple myeloma. More news on: Karyopharm Therapeutics Inc., Healthc...

Oasmia Pharmaceutical AB (NASDAQ: OASM ) +51% . More news on: Oasmia Pharmaceutical AB (publ), Tyme Technologies, Inc., DBV Technologies S.A., Stocks on the move, Read more ...

During its conference call this afternoon, Karyopharm Therapeutics ( KPTI +37.3% ) stated that the wholesale (WAC) price of XPOVIO (selinexor) will be $22K per month. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ) has disclosed in a filing that its chief commercial officer, Anand Varadan, resigned from the company effective this Friday, July 5. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news Read more ...

-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Age...